Xylo Technologies EBIT

The latest EBIT for XYLO is $-8.5M as of December 2024. That compares with $-16M in the prior-year period — up 48.2% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Xylo Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, XYLO's EBIT moved from $-16M to $-8.5M — a 48.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xylo Technologies's operating scale or balance-sheet position.

Against Healthcare companies, XYLO currently prints $-8.5M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Xylo Technologies's growth, margins, and balance sheet.

A EBIT figure of $-8.5M for XYLO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting XYLO's EBIT ($-8.5M), review year-over-year change from $-16M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.